Is ipsilateral administration of COVID-19 vaccine boosters the optimal approach?
- PMID: 38251468
- PMCID: PMC10628342
- DOI: 10.1016/j.ebiom.2023.104853
Is ipsilateral administration of COVID-19 vaccine boosters the optimal approach?
Conflict of interest statement
Declaration of interests M.S. has received grant support from Astellas and Biotest to the organization Saarland University outside the submitted work, and honoraria and travel support for lectures from Biotest, MSD, Takeda, Qiagen and Novartis, and for advisory boards from Moderna, Biotest, MSD and Takeda outside of the submitted work. T.S. has received travel support from Biotest for attending a meeting outside the submitted work. S.L.B. has participated in advisory boards with Shionogi and Pfizer outside the submitted work. B.C.G. has received honoraria for lectures from BioNTech, Moderna, Sanofi, CSL Seqirus, and GSK, and travel support from Pierre Fabre outside of the submitted work. All other authors of this manuscript have no conflicts of interest to disclose.
Comment on
-
Differences in SARS-CoV-2 specific humoral and cellular immune responses after contralateral and ipsilateral COVID-19 vaccination.EBioMedicine. 2023 Sep;95:104743. doi: 10.1016/j.ebiom.2023.104743. Epub 2023 Aug 11. EBioMedicine. 2023. PMID: 37574375 Free PMC article.
-
Is ipsilateral administration of COVID-19 vaccine boosters the optimal approach?EBioMedicine. 2023 Dec;98:104852. doi: 10.1016/j.ebiom.2023.104852. Epub 2023 Oct 31. EBioMedicine. 2023. PMID: 38251467 Free PMC article. No abstract available.
References
-
- Grupel D., Pasternak Y., Schonmann Y. Effect of same-arm versus cross-arm administration of sequential doses of BNT162b2 on short-term vaccine effectiveness-a retrospective cohort study. Clin Microbiol Infect. 2023;29(4):540.e1–540.e7. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
